BR112015014174A2 - composição de vacina para indivíduos virgens - Google Patents

composição de vacina para indivíduos virgens

Info

Publication number
BR112015014174A2
BR112015014174A2 BR112015014174A BR112015014174A BR112015014174A2 BR 112015014174 A2 BR112015014174 A2 BR 112015014174A2 BR 112015014174 A BR112015014174 A BR 112015014174A BR 112015014174 A BR112015014174 A BR 112015014174A BR 112015014174 A2 BR112015014174 A2 BR 112015014174A2
Authority
BR
Brazil
Prior art keywords
individuals
virgin
vaccine
vaccine composition
composition
Prior art date
Application number
BR112015014174A
Other languages
English (en)
Portuguese (pt)
Inventor
Maltais Anna-Karin
Arwidsson Hans
Original Assignee
Eurocine Vaccines Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurocine Vaccines Ab filed Critical Eurocine Vaccines Ab
Publication of BR112015014174A2 publication Critical patent/BR112015014174A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112015014174A 2012-12-17 2013-12-17 composição de vacina para indivíduos virgens BR112015014174A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12197522.1A EP2742952A1 (en) 2012-12-17 2012-12-17 Influenza vaccine composition
PCT/EP2013/077006 WO2014095943A1 (en) 2012-12-17 2013-12-17 Vaccine composition for naive subjects

Publications (1)

Publication Number Publication Date
BR112015014174A2 true BR112015014174A2 (pt) 2017-07-11

Family

ID=47358019

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112015014174A BR112015014174A2 (pt) 2012-12-17 2013-12-17 composição de vacina para indivíduos virgens
BR112015014243A BR112015014243A8 (pt) 2012-12-17 2013-12-17 composição de vacina para uso em populações imunocomprometidas e uso da mesma

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112015014243A BR112015014243A8 (pt) 2012-12-17 2013-12-17 composição de vacina para uso em populações imunocomprometidas e uso da mesma

Country Status (12)

Country Link
US (2) US20150306204A1 (enExample)
EP (4) EP2742952A1 (enExample)
JP (3) JP2016502997A (enExample)
KR (3) KR20150132092A (enExample)
CN (3) CN104884085A (enExample)
AU (2) AU2013360889C1 (enExample)
BR (2) BR112015014174A2 (enExample)
CA (2) CA2895023A1 (enExample)
HK (2) HK1212611A1 (enExample)
MX (2) MX2015007688A (enExample)
RU (2) RU2661408C2 (enExample)
WO (2) WO2014095943A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2621524A1 (en) * 2010-09-30 2013-08-07 Eurocine Vaccines AB Improved vaccine compositions
AU2015323334B2 (en) * 2014-09-26 2021-02-25 Seqirus UK Limited Vaccination of immunocompromised subjects
HUE060456T2 (hu) * 2014-09-26 2023-03-28 Seqirus Uk Ltd Immunkompromittált alanyok oltása
RU2634247C2 (ru) * 2015-09-28 2017-10-24 Федеральное государственное бюджетное научное учреждение "СЕВЕРО-КАВКАЗСКИЙ ЗОНАЛЬНЫЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ВЕТЕРИНАРНЫЙ ИНСТИТУТ" (ФГБНУ СКЗНИВИ) Способ стимуляции иммунного ответа и препарат для его осуществления
WO2019108928A1 (en) * 2017-11-30 2019-06-06 Ohio State Innovation Foundation Mucoadhesive nanoparticle entrapped influenza virus vaccine delivery system
EP4135519B1 (en) * 2020-04-16 2024-09-25 Bayer Aktiengesellschaft Active compound combinations and fungicide compositions comprising those
PL4135520T3 (pl) * 2020-04-16 2025-02-17 Bayer Aktiengesellschaft Kombinacje związków aktywnych i kompozycje grzybobójcze je zawierające
WO2021209364A1 (en) * 2020-04-16 2021-10-21 Bayer Aktiengesellschaft Active compound combinations and fungicide compositions comprising those
CN112063699B (zh) * 2020-09-16 2021-06-18 成都市疾病预防控制中心 一种用于研究hiv感染者免疫衰老机制的系统
US20250177515A1 (en) * 2022-01-10 2025-06-05 The Children's Medical Center Corporation Methods and compositions relating to immunization of immune distinct patients

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9602280D0 (sv) 1996-06-10 1996-06-10 Pharmatrix Ab Immunstimulerande lipidformulering
SE9900496D0 (sv) 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine formulation
US8410248B2 (en) 1999-03-12 2013-04-02 Human Genome Sciences Inc. HWBAO62 polypeptides
US20030072764A1 (en) 2001-04-05 2003-04-17 O'hagan Derek Mucosal boosting following parenteral priming
US20050208602A1 (en) 2001-08-10 2005-09-22 Rosen Craig A 89 human secreted proteins
WO2004042000A2 (en) 2002-05-17 2004-05-21 Human Genome Sciences, Inc. 157 human secreted proteins
WO2004047862A1 (en) 2002-11-26 2004-06-10 Eurocine Ab Novel amine-based adjuvant
CN103446582A (zh) 2003-08-11 2013-12-18 财团法人阪大微生物病研究会 包含诱导粘膜免疫的佐剂的新型疫苗
AU2006247188A1 (en) 2005-05-18 2006-11-23 Children's Hospital & Research Center At Oakland Methods and compositions for immunizing against chlamydia infection
CN101213199B (zh) 2005-06-30 2013-12-18 卫材R&D管理有限公司 用于制备免疫佐剂的化合物
CN101257919B (zh) 2005-08-05 2012-08-29 国立大学法人德岛大学 可以由选择性产生IgA抗体向产生IgA和IgG两种抗体转换的抗原药物载体和使用该载体的经鼻·粘膜疫苗
RU2323742C1 (ru) * 2007-02-15 2008-05-10 Государственное учреждение Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова (ГУ НИИВС им. И.И. Мечникова) Способ повышения иммуногенности инактивированной гриппозной вакцины
WO2009071633A1 (en) * 2007-12-06 2009-06-11 Glaxosmithkline Biologicals S.A. Influenza composition
EP2293813A4 (en) 2008-05-23 2012-07-11 Univ Michigan NANO EMULSION VACCINES
AU2009293595A1 (en) 2008-05-23 2010-03-25 The Regents Of The University Of Michigan Nanoemulsion adjuvants
US20130178383A1 (en) 2008-11-12 2013-07-11 David Spetzler Vesicle isolation methods
KR101704988B1 (ko) 2009-05-28 2017-02-08 큐알엔에이, 인크. 항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
EP2621524A1 (en) 2010-09-30 2013-08-07 Eurocine Vaccines AB Improved vaccine compositions

Also Published As

Publication number Publication date
CN104884085A (zh) 2015-09-02
BR112015014243A2 (pt) 2017-07-11
RU2661408C2 (ru) 2018-07-16
BR112015014243A8 (pt) 2019-10-08
JP2016502997A (ja) 2016-02-01
AU2013360890A1 (en) 2015-07-02
KR20210007042A (ko) 2021-01-19
JP2019112448A (ja) 2019-07-11
EP3431101A1 (en) 2019-01-23
AU2013360889B2 (en) 2016-12-01
HK1212611A1 (zh) 2016-06-17
US20150306205A1 (en) 2015-10-29
MX2015007688A (es) 2015-09-07
KR20150132092A (ko) 2015-11-25
RU2661407C2 (ru) 2018-07-16
CN112826929A (zh) 2021-05-25
WO2014095944A1 (en) 2014-06-26
AU2013360889A1 (en) 2015-07-02
WO2014095943A1 (en) 2014-06-26
CA2895023A1 (en) 2014-06-26
RU2015129077A (ru) 2017-01-23
JP2016502996A (ja) 2016-02-01
AU2013360890B2 (en) 2017-04-13
HK1213492A1 (zh) 2016-07-08
EP2931308B1 (en) 2018-10-10
AU2013360889C1 (en) 2017-06-08
EP2931307A1 (en) 2015-10-21
EP2742952A1 (en) 2014-06-18
CN104870010A (zh) 2015-08-26
MX2015007753A (es) 2016-01-08
KR20150132093A (ko) 2015-11-25
EP2931307B1 (en) 2018-09-12
EP2931308A1 (en) 2015-10-21
RU2015129028A (ru) 2017-01-23
US11065325B2 (en) 2021-07-20
CA2895028A1 (en) 2014-06-26
US20150306204A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
BR112015014174A2 (pt) composição de vacina para indivíduos virgens
CY1122189T1 (el) Ιονικες υδατικες συνθεσεις
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
BR112014024672A8 (pt) Composições farmacêuticas para terapia de combinação
CR20170279A (es) Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico
CL2012001836A1 (es) Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros.
EA028928B9 (ru) 2'-замещенные карбануклеозидные аналоги для противовирусного лечения
MX383706B (es) Composiciones de cenicriviroc y métodos para elaborarlas y usarlas.
BR112015003590A8 (pt) Métodos para tratamento ou prevenção da asma por administração de um antagonista de il-4r
BR112014026703A2 (pt) inibidores de dna-pk
CY1118813T1 (el) Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων
BR112014016810A8 (pt) composições e métodos para tratamento de distúrbios metabólicos
BR112015001313A2 (pt) composições de vacina
BR112013009649A2 (pt) composição imunogênica, métodos para provocar uma resposta imune protetora em um paciente humano e para fornecer proteção imune em seres humanos contra doença, e, uso de uma composição
BR112014018953A8 (pt) Derivados de lupano triterpenoide e uso farmacêutico dos mesmos
BR112015007814A2 (pt) diagnóstico, prevenção e tratamento de doenças da articulação
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
CL2017003066A1 (es) Composiciones de carbonato de calcio amorfo para administración mediante inhalación, sublingual o bucal
BR112012012862A2 (pt) composição farmacêutica compreendendo oligopeptídeos
BR112015017251A8 (pt) composições farmacêuticas compreendendo doadores de nitroxil, misturas e usos das referidas composições farmacêuticas
DOP2012000279A (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona
BRPI0915119B8 (pt) uso de iota carragenano
MX2017012272A (es) Solucion para inhalacion de tiotropio para nebulizacion.
CO6640216A2 (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
BR112012015202A2 (pt) "iota - e/ou kappa-carrgenado junto com um inibidor da neuraminidase, método para o tratamento profilático ou terapêutico de um sintoma, condição ou doença, composição farmacêutica,e, kit de partes".

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements